Sun Pharma buys 14 of Novartis's brands in Japan for $293 mn
Acquisition of prescription brands, with annualized revenues of $160 million, marks Sun Pharma's entry into the Japanese market29-03-2016
29-03-2016
Rights issue of Fortune Financial, Sun Pharma to open on Monday
Individually, Sun Pharma is planning to mop up `250 crore, while Fortune Financial intends to garner `204 crore27-03-2016
Sun Pharma to sell AstraZeneca's diabetes drug in India
Under the agreement, Sun Pharma will promote and distribute AstraZenceca's dapagliflozin under the brand name Oxra23-03-2016
Sun Pharma and AstraZeneca India enter partnership in Type 2 diabetes
Sun Pharmaceutical Industries Ltd has informed BSE regarding a Press Release dated March 23, 2016 titled "Sun Pharma and AstraZeneca India enter partnership in Type 2 diabetes".23-03-2016
Sun Pharma arm Taro gets board nod for $250-mshare buyback
Israeli drug-maker Taro Pharmaceutical Industries said that its board of directors has approved a$250-millionshare repurchase of its ordinary shares. Taro was acquired by Sun Pharma in ...16-03-2016
Sun Pharma Recalls 3.8 Lakh Cartons of Osteoporosis Drug in US: Report
Around 3.8 lakh cartons of an osteoporosis drug manufactured by domestic drug major Sun Pharmaceutical Industries are being recalled in the US and Puerto Rico due to presence of "unknown impurity".10-03-2016
Sun Pharma ups focus on consumer healthcare business with Pepmelt launch
India's largest drugmaker is looking for a share of the market for antacids dominated by GlaxoSmithKline in India08-03-2016
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
Jayant Sanghvi has submitted the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 to BSE02-03-2016
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
Sudhir Valia has submitted the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 to BSE01-03-2016
More inspections due to rising drug imports from India: USFDA
The federal agency had taken action against companies like Sun Pharma last year & earlier Ranbaxy among other Indian drug companies.27-02-2016